Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
囊泡 肿瘤
/
细胞周期
其他抑制剂/激动剂 表观遗传学 TGF-beta/Smad 干细胞 外泌体 肿瘤表观遗传和基因调控 肿瘤干细胞 Wnt Notch
/
其他
转化生长因子-β SRPK PKC
/ Enzastaurin

恩扎妥林 /Enzastaurin {[allProObj[0].p_purity_real_show]}

货号：A473249 同义名： LY317615

Enzastaurin is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε.

Enzastaurin 化学结构 CAS号：170364-57-5
Enzastaurin 化学结构
CAS号：170364-57-5
Enzastaurin 3D分子结构
CAS号：170364-57-5
Enzastaurin 化学结构 CAS号：170364-57-5
Enzastaurin 3D分子结构 CAS号：170364-57-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Enzastaurin 纯度/质量文件 产品仅供科研

货号：A473249 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 ALK1 ↓ ALK2 ↓ ALK3 ↓ ALK4 ↓ ALK6 ↓ Smad3 ↓ TGF-β ↓ TGFβRI/ALK5 ↓ TGFβRII ↓ 其他靶点 纯度
LDN193189 ++++

ALK1, IC50: 0.8 nM

 		++++

ALK2, IC50: 0.8 nM

 		+++

ALK3, IC50: 5.3 nM

 		+++

ALK6, IC50: 16.7 nM

 		99%+
LDN-212854 ++++

ALK1, IC50: 2.4 nM

 		++++

ALK2, IC50: 1.3 nM

 		+

ALK3, IC50: 85.8 nM

 		+

ALK4, IC50: 2133 nM

 		+

ALK5, IC50: 9276 nM

 		99%+
ML347 ++

ALK1, IC50: 46 nM

 		++

ALK2, IC50: 32 nM

 		98%
K02288 ++++

ALK1, IC50: 1.8 nM

 		++++

ALK2, IC50: 1.1 nM

 		++

ALK3, IC50: 34.4 nM

 		+++

ALK6, IC50: 6.4 nM

 		99%+
LDN-193189 dihydrochloride ++++

ALK1, IC50: 0.8 nM

 		++++

ALK2, IC50: 0.8 nM

 		+++

ALK3, IC50: 5.3 nM

 		+++

ALK6, IC50: 16.7 nM

 		99%
LDN-214117 ++

ALK2, IC50: 24 nM

 		98%
DMH-1 +

ALK2, IC50: 107.9 nM

 		99%+
SB-505124 +

ALK4, IC50: 129 nM

 		++

ALK5, IC50: 47 nM

 		99%+
Vactosertib +++

ALK4, IC50: 13 nM

 		+++

ALK5, IC50: 11 nM

 		99%+
Alantolactone ✔ 98%
SIS3 ✔ 97%
Pirfenidone ✔ 98%
Hesperetin ✔ 97%
RepSox ++++

TGFβR1(ALK5), IC50: 4 nM

 		98%
GW788388 +++

ALK5, IC50: 18 nM

 		98%
LY364947 ++

TGFβRI, IC50: 59 nM

 		+

TGFβRII, IC50: 0.4 μM

 		98%
SD-208 ++

TGF-βRI (ALK5), IC50: 48 nM

 		98%
SB-525334 +++

TGFβR1(ALK5), IC50: 14.3 nM

 		99%+
LY2109761 ++

TβRI, Ki: 38 nM

 		+

TβRII, Ki: 300 nM

 		99%+
Galunisertib ++

TβRI, IC50: 56 nM

 		98%
SB 431542 +

ALK5, IC50: 94 nM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
产品名称 PKC ↓ PKCα ↓ PKCβ ↓ PKCγ ↓ PKCδ ↓ PKCε ↓ PKCζ ↓ PKCη ↓ PKCθ ↓ 其他靶点 纯度
Daphnetin +

PKC, IC50: 25.01 μM

 		PKA,EGFR 95%
Dequalinium Chloride 99%+
Quercetin ✔ Sirtuin,Src 97%
Myricetrin ✔ 96%
Go 6983 +++

PKCα, IC50: 7 nM

 		+++

PKCβ, IC50: 7 nM

 		+++

PKCγ, IC50: 6 nM

 		+++

PKCδ, IC50: 10 nM

 		++

PKCζ, IC50: 60 nM

 		99%+
Go6976 +++

PKC, IC50: 7.9 nM

 		++++

PKCα, IC50: 2.3 nM

 		+++

PKCβ1, IC50: 6.2 nM

 		FLT3 99%+
Bisindolylmaleimide I +++

PKCα, IC50: 20 nM

 		+++

PKCβ1, IC50: 17 nM

PKCβ2, IC50: 16 nM

 		+++

PKCγ, IC50: 20 nM

 		99%+
Lawsone methyl ether ✔ 99%
Sotrastaurin ++++

PKCα, Ki: 0.95 nM

 		++++

PKCβ1, Ki: 0.64 nM

 		++++

PKCδ, Ki: 2.1 nM

 		++++

PKCε, Ki: 3.2 nM

 		++++

PKCη, Ki: 1.8 nM

 		++++

PKCθ, Ki: 0.22 nM

 		99%+
Enzastaurin ++

PKCα, IC50: 39 nM

 		+++

PKCβ, IC50: 6 nM

 		+

PKCγ, IC50: 83 nM

 		+

PKCε, IC50: 110 nM

 		98%
Midostaurin ++

PKCα, IC50: 22 nM

 		++

PKCβ1, IC50: 30 nM

PKCβ2, IC50: 31 nM

 		++

PKCγ, IC50: 24 nM

 		+

PKCδ, IC50: 330 nM

 		+

PKCε, IC50: 1.25 μM

 		+

PKCη, IC50: 160 nM

 		99%
Ro 31-8220 mesylate ++++

PKCα, IC50: 5 nM

 		+++

PKCβ1, IC50: 24 nM

PKCβ2, IC50: 14 nM

 		++

PKCγ, IC50: 27 nM

 		++

PKCε, IC50: 24 nM

 		99%+
Staurosporine ++++

PKCα, IC50: 2 nM

 		++++

PKCγ, IC50: 5 nM

 		+++

PKCδ, IC50: 20 nM

 		++

PKCε, IC50: 73 nM

 		++++

PKCη, IC50: 4 nM

 		99%+
Ruboxistaurin HCl +

PKCα, IC50: 0.36 μM

 		++++

PKCβ1, IC50: 4.7 nM

PKCβ2, IC50: 5.9 nM

 		+

PKCγ, IC50: 0.3 μM

 		+

PKCδ, IC50: 0.25 μM

 		++

PKCη, IC50: 0.052 μM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Enzastaurin 生物活性

靶点

  • PKCβ

    PKCβ, IC50:6 nM

  • PKCγ

    PKCγ, IC50:83 nM

  • PKCε

    PKCε, IC50:110 nM

  • PKCα

    PKCα, IC50:39 nM
描述 The protein kinase C (PKC) family of serine-threonine protein kinases has been implicated in the processes that control cell proliferation, motility, invasion, and apoptosis. Enzastaurin is an ATP-competitive, selective inhibitor of PKC with IC50 values of 6nM, 39nM, 83nM and 110nM for PKCβ, PKCα, PKCγ, and PKCε, respectively[3]. In vitro, Enzastaurin can inhibit cell proliferation, including H460, LXF289, H1395, A427, A549, and H1299 cell lines with IC50 values ranging in 5 - 12 μM[4]. Enzastaurin suppressed the proliferation of U87MG glioblastoma cells, PC-2 prostate carcinoma cells, and HCT116 colon carcinoma cells with concentrations ranging from 1 – 10 μM. K-562, MOLT-4, HOP-92, and PC-3 were the most sensitive cell lines to enzastaurin. However, Prostate cancer cell line DU-145; Breast cancer cell lines HS-578T, BT-549, and T-47D; Melanoma cell line MALme-3M; Lung cancer cell lines HOP-62, NCIH23, NCI-H322m, and NCI-460. Ovarian cancer cell lines OVCAR-5 and SK-OV-3; The renal cell lines 786-0, A498, ACHN, RXF393, and TK-10 were not affected by Enzastaurin. Enzastaurin induced HT116 and U87MG cell apoptosis in the low micromolar range in 1 – 4 μM. Enzastaurin at 1 μM inhibited the activity of PKCβ, PKCγ, PKCδ, PKCθ, PKCξ, and PKCε by about 90% or more but did not show significant inhibition of PKCμ and PKCι. At 1 μM, enzastaurin also suppressed the activity of p70S6, PKCζ, and PKCη by nearly 50%. Treatment of HCT116 and U87MG cells with 1 μM enzastaurin did not inhibit ERK activity[3]. In vivo, oral administration with enzastaurin at 75 mg/kg twice daily for 21 days significantly suppressed the growth of both HCT116 colon carcinoma and U87MG glioblastoma xenografts in mice. In both cultured HCT116 cells and in xenograft tumor tissues from the same cell lines, enzastaurin treatment suppressed GSK3h-Ser9 phosphorylation, indicating that GSK3h-Ser9 phosphorylation may serve as a reliable marker for enzastaurin activity[3]. The phase I clinical trials for enzastaurin have shown that oral administration at 525 mg/d yields -2 μM mean steady-state plasma exposure of enzastaurin and its analytes. Enzastaurin has successfully advanced to phase II clinical trials for the treatment of refractory glioblastoma and DLBCL[3].
作用机制 Enzastaurin selectively inhibits PKC activity by interacting competitively at its ATP-binding site[5].

Enzastaurin 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00052273 Adult Solid T... 展开 >>umor 收起 << Phase 1 Completed - United States, California ... 展开 >> Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States, 90095-1781 收起 <<
NCT00542919 T-Cell Lymphoma ... 展开 >> B-Cell Lymphoma 收起 << Phase 2 Completed - United States, California ... 展开 >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Anaheim, California, United States, 92801 Australia, Australian Capital Territory For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Garran, Australian Capital Territory, Australia, 2605 Australia, New South Wales For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gosford, New South Wales, Australia, 2250 Australia, Queensland For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Auchenflower, Queensland, Australia, 4066 Australia, Victoria For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Prahran, Victoria, Australia, 3181 Brazil For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Brasilia, Brazil, 70710-904 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Curitiba, Brazil, 81520-060 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Jau, Brazil, 17210-120 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Porto Alegre, Brazil, 90430-090 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. São Paulo, Brazil, 01323-903 India For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bangalore, India, 560017 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chennai, India, 6000 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kolkata, India, 700053 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Navrangpura, India, 380009 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Secunderabad, India, 800003 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Trivandrum, India, 695011 Mexico For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Monterrey, Mexico, 64460 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tepic, Mexico, 63000 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tlalpan, Mexico, 14080 Peru For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Lima, Peru, LIMA13 收起 <<
NCT03776071 Glioblastoma Phase 2 Not yet recruiting December 2022 -

Enzastaurin 参考文献

[1]Rovedo MA, Krett NL, et al. Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. J Invest Dermatol. 2011 Jul;131(7):1442-9.

[2]Graff JR, McNulty AM, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005 Aug 15;65(16):7462-9.

[3]Jeremy R. Graff, Ann M. McNulty, Kimberly Ross Hanna, et al. The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts. Cancer Res. 2005, 65(16): 7462-7469

[4]Körner A, Mudduluru G, Manegold C, Allgayer H. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer. 2010 Sep 7;103(6):802-11

[5]Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer. 2008 Sep 2;99(5):750-9

Enzastaurin 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.94mL

0.39mL

0.19mL

9.70mL

1.94mL

0.97mL

19.39mL

3.88mL

1.94mL

Enzastaurin 技术信息

CAS号170364-57-5
分子式C32H29N5O2
分子量 515.605
别名 LY317615
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Store in freezer, under -20°C
溶解度

DMSO: 7 mg/mL(13.58 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

15% Captisol+water 30 mg/mL suspension

Tags: Enzastaurin | LY317615 | PKC | SRPK | TGF-beta/Smad | AmBeed-信号通路专用抑制剂 | Enzastaurin 纯度/质量文件 | Enzastaurin 亚型比较 | Enzastaurin 生物活性 | Enzastaurin 临床数据 | Enzastaurin 参考文献 | Enzastaurin 实验方案 | Enzastaurin 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z